Rebamipide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Rebamipide
Rebamipide: Known uses and market status in India
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Rebamipide, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own known uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 5 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (9 of 9) – CDSCO approval status is not included in this data |
| Number of Listed Products | 9 (valid: 9) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| dry eye | licence in another country |
| gastric ulcer | licence in another country |
| peptic ulcer | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| gastritis |
| peptic ulcer disease |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 185346 | Rebator 100mg Tablet | strip of 10 tablets | Valid |
| 187266 | Rebam 100mg Tablet | strip of 10 tablets | Valid |
| 134965 | Mucogen 100mg Tablet | strip of 10 tablets | Valid |
| 184145 | Rebagen Tablet | strip of 10 tablets | Valid |
| 184375 | Rebagen-Otic Capsule | strip of 10 capsules | Valid |
| 85290 | Finetears Eye Drop | bottle of 10 ml Eye Drop | Valid |
| 186847 | Rebacer Eye Drop | bottle of 10 ml Eye Drop | Valid |
| 75168 | Eyesec Eye Drop | bottle of 10 ml Eye Drop | Valid |
| 190024 | Rebasoothe Eye Drop | packet of 10 ml Eye Drop | Valid |
Safety Considerations
- Drug Interactions: The interaction query completed, but it returned only a pharmacology target record (rebamipide at the CCK1 receptor in rat), not a clinical drug-drug interaction.
- Pharmacovigilance: A 2022 analysis of Korean adverse event reports compared rebamipide’s safety signals with other peptic ulcer and GERD drugs in the elderly.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.